Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
China has always been believed to be the land of promise for multinational pharmaceutical companies. However, up until recently many organisations have struggled to see a return on their investments. That may all be set to change though.
The country’s recent 2020 healthcare reforms aim to rapidly increase the pace of new drug approvals and fast track innovative treatments, opening up a whole new world of opportunities for the pharmaceutical industry.
Register now for our next live webinar in which emerging markets experts Marc Yates and Helen Ansell will explore China’s evolving healthcare environment, highlight the key changes affecting pharma and show you how to  build the market understanding required to launch a brand effectively in this exciting region.
When: Tuesday 16th April 2019Â
Time: 10:00 EST/ 15:00 GMT / 16:00 CEST
Register now to secure your place »
China’s key growth factors:
Fast track approvals: So far, over 180 foreign pharma products have been granted priority review and will likely hit the market within the next few years.
From an ability to pay to willingness to pay: By 2022 more than half of the urban population will be defined as upper middle class and as incomes rise so does willingness to pay for quality healthcare.
Shifting disease patterns:Â Diseases of affluence are also on the rise and the benefits of urban life have resulted in an aging population and an explosion in age-related conditions.
What are the key takeaways in this webinar?Â
1. China 101Â
An overview of the healthcare environment in China
2. What’s changed?
The key opportunities under China’s 2020 healthcare reform
3. Where to play? How to win?
Design an effective marketing strategy with insights that prepare you for optimal success.
4. Gain answers to your key questions
Start the conversation by submitting your questions in advance when you register.
Register now to secure your place »
If you are unable to attend but would like to view the recording, register now and we will send you a unique link to download it as soon as it is ready.
This content was provided by Research Partnership
Company Details
Latest Content from Research Partnership
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.
The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address...
The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our...
Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver...
PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...
Authored by Paul Reed and Anabelle Gall
Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its...
Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report...
Artificial intelligence (AI) in market research has surged in recent years, with a flow of innovative tools and techniques which have the potential to revolutionize the landscape. But to unlock...
Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine.